You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Wireless Digital Link Between Hearing Aids
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: N/ADESCRIPTION (provided by applicant): This proposed project will create an ultra-low power, digital wireless transceiver as an integrated circuit (IC) which will enable communication between hearing aids worn in the left and right ears in a binaural system. Wireless synchronization between the digital signal processors of two hearing instruments is a new technology for next generation hearing inst ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Wireless Digital Link Companion Microphone
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: N/ADESCRIPTION (provided by applicant): The objective of this project is to develop a hearing aid and wireless companion microphone system based on new, highly-innovative, very low-power ultra-wideband impulse radio technology. The phase I program successfull y established the feasibility of fully integrating an ultra-wideband (UWB) impulse radio transceiver and antenna system inside a behind-the-ear ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
A device containing immobilized chelator to remove aluminum from TPN solutions
SBC: ALKYMOS, INC Topic: N/ADESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Innovative Approaches to the Development of Corrosion Resistant Aircraft Alloys
SBC: ATI, INC. Topic: N08T010Aluminum alloys are known to suffer from Stress Corrosion Cracking(SCC). SCC of high strength alloys can proceed rapidly, and can lead to devastating structural failures. However, a solid understanding of combined interactions of metallurgical, environmental and mechanical factors surrounding the crack tip during SCC is still elusive. Therefore, Al alloy developement for high corrosion resistance ...
STTR Phase I 2008 Department of DefenseNavy -
Delivery of Sleeping Beauty Transposons to Dog Liver for Gene Therapy
SBC: DISCOVERY GENOMICS, INC. Topic: N/ADESCRIPTION (provided by applicant): The overall goal of Discovery Genomics, Inc. is to develop the Sleeping Beauty transposon system for human gene therapy. To achieve this to treat hemophilia, we must be able to direct uptake and long-term expression of therapeutic genes in targeted tissues such as the liver. Only one method of plasmid delivery has been effective for high-level gene expression ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
New anti-complement therapy to reduce reperfusion injury: Phase II
SBC: ENDOPROTECH, INC. Topic: N/ADESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to develop a local anti-complement therapy for donor organ e x vivo application that will reduce complement-induced injury to the vascular endothelium. An unavoidable consequence of transplantation (allog ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
PET and SPECT Ligands for Imaging Apoptosis
SBC: IMMUNOCHEMISTRY TECHNOLOGIES, LLC Topic: N/ADESCRIPTION (provided by applicant): PET and SPECT Ligands for Imaging Neuronal Apoptosis Abstract: Activation of the intracellular caspase cascade is a well understood signaling mechanism that results in apoptosis. The identification of apoptotic events i n vivo has important applications for detecting cell death induced by disease, injury, therapeutics, or normal tissue development and different ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Potential anti-relapse drugs: a plant genomics approach
SBC: NAPROGENIX, INC. Topic: N/ADESCRIPTION (provided by applicant): Alcohol-induced neurodegeneration and the consequent dementia are important therapeutic targets in alcoholism. However, because alcohol-induced neurotoxicity has different mechanisms during the presence of alcohol and during its withdrawal, these are difficult targets for pharmacotherapy. Based on preclinical research, two types of neuroprotective compound, po ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Drug Therapy for Parkinson's Disease
SBC: NEOCYTEX BIOPHARMA, INC. Topic: N/ADESCRIPTION (provided by applicant): The total cost of caring for Parkinson's disease is about 25 billion per year in the United States. There is an urgent and unmet need for an effective treatment for the patients who have suffered debilitating loss of n eurons and motor function. Development of neuroregeneration therapy is an important goal because neurdegenerative diseases disable and kill mil ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Targeting drug delivery nanoparticles to sites of inflammation
SBC: POTENTIA PHARMACEUTICALS, INC Topic: N/ADESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of blindness for individ uals over fifty-five years of age that live in the industrialized world, affecting approximately 10 million people in the US and as many as 30 ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health